Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

ScinoPharm Taiwan receives the SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that ScinoPharm Taiwan Limited in Tainan, Taiwan has met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”).

19 Nov 2009

Expansion of Excelyte manufacturing plant completed at Midland

Integrated Environmental Technologies, Ltd. announces that Benchmark Performance Group, Inc., its exclusive worldwide distributor serving the oil and gas industry, has completed the expansion of its Excelyte® manufacturing plant at its Midland, Texas facility.

19 Nov 2009

Shamir Optical Industry discloses unaudited financial results for third-quarter 2009

Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the third quarter ended September 30, 2009.

18 Nov 2009

Third-quarter 2009 results announced by Tongjitang Chinese Medicines

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended September 30, 2009 and the repurchase of ordinary shares in a private transaction.

18 Nov 2009

KAI Pharmaceuticals to receive manufacturing services from Formatech

Today, Formatech announced that they have selected KAI Pharmaceuticals, Inc. and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program.

18 Nov 2009

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.

18 Nov 2009

Capsugel to have exclusive rights to Appian Labs' AppiForm Modular Release System technology

Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design and delivery, has announced an exclusive Development and Commercial License Agreement for the company’s AppiForm™ Modular Release System with Capsugel, the world's leading provider of dosage form solutions to the pharmaceutical and related healthcare industries. The agreement provides for Capsugel to utilize the AppiForm Modular Release System for customizable drug delivery profiles.

17 Nov 2009

Bavarian Nordic awarded a new contract for developing a freeze-dried version of its IMVAMUNE smallpox vaccine

Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.

17 Nov 2009

Neuralstem provides financial and business updates for third-quarter 2009

Neuralstem, Inc. today provided a financial and business update for the third quarter ended September 30, 2009.

17 Nov 2009

China Sky One Medical reports financial results for third-quarter 2009

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced record financial results for the third quarter of 2009.

17 Nov 2009

Second-quarter fiscal 2010 results announced by China-Biotics

China-Biotics, Inc., a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for the second quarter of its 2010 fiscal year, ended September 30, 2009.

17 Nov 2009

Presentations to highlight durability and efficacy of urethral bulking agents

Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.

17 Nov 2009

IntelGenx completes first successful human study of an anti-migraine film

IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.

17 Nov 2009

Genzyme receives FDA complete response letter for its Lumizyme marketing application

Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.

17 Nov 2009

Remedent net sales decreases to $1.8 million in fiscal second quarter ended September 30, 2009

Remedent, Inc., an international company specializing in the research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the fiscal second quarter ended September 30, 2009 (in U.S. dollars).

17 Nov 2009

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.

17 Nov 2009

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Targeted Genetics Corporation today announced its financial results for the third quarter ended September 30, 2009.

17 Nov 2009

Additional vaccine for 2009 H1N1 flu approved by FDA

The U.S. Food and Drug Administration announced that it has approved a fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC.

16 Nov 2009

Dyadic International reports financial results for the third quarter of 2009

Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors’ report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic’s website at www.dyadic.com.

16 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Manufacturing News and Research

Further Reading

ScinoPharm Taiwan receives the SafeBridge Potent Compound Safety Certification

Expansion of Excelyte manufacturing plant completed at Midland

Shamir Optical Industry discloses unaudited financial results for third-quarter 2009

Third-quarter 2009 results announced by Tongjitang Chinese Medicines

KAI Pharmaceuticals to receive manufacturing services from Formatech

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

Capsugel to have exclusive rights to Appian Labs' AppiForm Modular Release System technology

Bavarian Nordic awarded a new contract for developing a freeze-dried version of its IMVAMUNE smallpox vaccine

Neuralstem provides financial and business updates for third-quarter 2009

China Sky One Medical reports financial results for third-quarter 2009

Second-quarter fiscal 2010 results announced by China-Biotics

Presentations to highlight durability and efficacy of urethral bulking agents

IntelGenx completes first successful human study of an anti-migraine film

Genzyme receives FDA complete response letter for its Lumizyme marketing application

Remedent net sales decreases to $1.8 million in fiscal second quarter ended September 30, 2009

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Additional vaccine for 2009 H1N1 flu approved by FDA

Dyadic International reports financial results for the third quarter of 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News